Issue Contents:  Feb 8, 2010

• Carping Over PARPs: Buyout Equals 'Negative' for BioMarin?
• Optimer Reports More Good Data for Phase III Fidaxomicin
• Gene Panel Recommendations Called a Patent 'Slippery Slope'
• Myriad Ruling Could Have Broad Biotech Implications
• We've Come a Long Way, Baby, and We're Going a Lot Further
• Privately Held Specialty Pharma EUSA Gets $25M Credit Facility
• Clinic Roundup
• Other News To Note
• Bench Press

      The above issue is also available as one PDF File